At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 112 target
Drug / intervention
Prizloncabtagene autoleucelbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b/2 Study of a Anti-CD19/CD20 Bispecific CAR-T Therapy (C-CAR039/Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating Prizloncabtagene autoleucel for Relapsed/Refractory Large B-Cell Lymphoma. Currently recruiting, targeting 112 participants across 15 sites.
Detailed Summary
This is a multicenter, single arm, open-label study. The purpose of the study is to evaluate safety of Prizloncabtagene Autoleucel (Prizlon-cel) and establish the recommended Phase 2 dose (RP2D) (Phase 1b) and to evaluate the efficacy of Prizlon-cel (Phase 2) in patients with relapsed or refractory large b-cell lymphoma (LBCL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
202320242025202620272028
Enrollment StartFeb 2023
First PostedApr 2023
TodayJul 2026
Primary CompletionMar 2027
Study CompletionJun 2028
First PostedApr 6, 2023
Enrollment StartFeb 22, 2023
Primary CompletionMar 31, 2027
Study CompletionJun 30, 2028
TodayJul 1, 2026
Enrollment to primary: 4.1 yearsPosted 3.2 years agoPrimary completion in 9 months
Interventions
Prizloncabtagene autoleucelbiological
Prizlon-cel is a novel 2nd generation 4-1BB bispecific chimeric antigen receptor T-cell (CAR-T) targeting both CD19 and CD20 antigens